Patzschke K, Wegner L A
Arzneimittelforschung. 1977;27(6):1152-8.
14C-Labelled D-penicillamine [D-(--)-alpha-amino-beta-mercapto-isovaleric acid; Trolovol] was administered to rats in doses of 10 to 50 mg/kg body weight orally or i.v. A dose of 0.25 mg per rat was used for intra-articular injection (knee joint). 4 h after a single i.v. administration about 30% of the given amount were detected in the animal. This amount of activity was located predominantly in skin and connective tissues and was eliminated very slowly. 2 days after administration 20 (i.v.) or 10 (p.o.)%, resp., of the radioactivity administered were found in the animal, in any case half of it in the skin. In comparison to the skin and the connective tissues, the parenchymatous organs and the central nervous system showed distinctly lower concentrations. The activity is eliminated mainly with the urine: 80 (i.v.) or 50 (p.o.)%, resp., of the administered activity were eliminated renally within 48 h. 90% of it were excreted within 6 (i.v.) or 7 (p.o.) h, resp., after administration. Less than 2 (i.v.) and approx. 40 (p.o.)%, resp., of the given activity were found in the faeces collected for 2 days. The extent of gastrointestinal absorption was about 2/3 of the dose administered. Up to 24 h after the three modes of administration distinctly detectable concentrations were to be located in the lig. patellae of the knee joints, somewhat lower values in the ligaments between the articular cartilages. Studies carried out on rats in parallel with an arthritis experimentally induced (secondary phase, after injection of Freund's adjuvant) demonstrated the same activity distribution compared with the pattern which was obtained on healthy rats.
将14C标记的D-青霉胺[D-(-)-α-氨基-β-巯基异戊酸;曲洛伏尔]以10至50mg/kg体重的剂量口服或静脉注射给大鼠。每只大鼠关节内注射(膝关节)的剂量为0.25mg。单次静脉注射后4小时,在动物体内检测到约30%的给药量。该活性量主要位于皮肤和结缔组织中,且消除非常缓慢。给药2天后,在动物体内分别发现静脉注射组20%或口服组10%的给药放射性,无论如何其中一半在皮肤中。与皮肤和结缔组织相比,实质器官和中枢神经系统的浓度明显较低。活性主要通过尿液消除:静脉注射组80%或口服组50%的给药活性在48小时内通过肾脏消除。其中90%在给药后6小时(静脉注射)或7小时(口服)内排出。在收集2天的粪便中分别发现静脉注射组少于2%和口服组约40%的给药活性。胃肠道吸收程度约为给药剂量的2/3。在三种给药方式后长达24小时,膝关节的髌韧带中可检测到明显的浓度,关节软骨间韧带中的浓度略低。对实验性诱导关节炎(二期,注射弗氏佐剂后)的大鼠进行的平行研究表明,与健康大鼠相比,其活性分布模式相同。